Figure 3. Synergistic αEpCAM/αCD133 Cytokine Release.

Unactivated PBMCs were co-cultured with media, 100 nM 1DD/αCD3 CSANS, 100 nM αCD133/αCD3 CSANs, 100 nM αEpCAM/αCD3 CSANs, or both 50 nM αCD133/αCD3 and 50 nM αEpCAM/αCD3 CSANs to generate non-labeled PBMCS, non-targeted CSANs, αCD133 CSANs, αEpCAM CSANs or dual targeting αCD133/αEpCAM CSANs, respectively. Generated constructs were incubated in the presence of no target cells, U87-MG cells (EpCAM^negCD133^neg), MCF-7 cells (EpCAM^highCD133^neg), HT-29 cells (EpCAM^highCD133^pos), or MDA-MB-231 cells (EpCAM^lowCD133^{partial pos}). Following the 24-hour incubation, the media was analyzed for (A) IL-2 and (B) IFN-γ. Data shown was obtained from one donor (n=3), but representative of three donors. *P<0.05, by 2-tailed Student’s t test and one-way ANOVA.